China NMPA Drug Inspection - Suzhou Homesun Pharmaceutical Co., Ltd. - North American ginseng

The Shanghai Municipal Food and Drug Administration (SMFDA) issued an announcement on April 9, 2018, detailing the results of its 2018 drug and pharmaceutical packaging material supervision and sampling inspections. These inspections aimed to ensure the quality and safety of products on the market, regulating drug and packaging material manufacturers, distributors, and users.Several companies were identified for non-compliant products. Suzhou Boyuan Pharmaceutical Co., Ltd. was cited for deficiencies in Polygonum multiflorum (He Shou Wu) and Glehnia littoralis (Bei Sha Shen) processed slices, specifically related to "Content Determination" and "Sulfur Dioxide Residue," referencing the 2015 Chinese Pharmacopoeia. Shanghai First People's Hospital's Clodisongol Cream exhibited "Content Difference" against internal standards. Suzhou Chunhuitang Pharmaceutical Co., Ltd.'s Fennel Seeds also failed "Content Determination." Additionally, Shanghai Huayi Group Huayuan Chemical Co., Ltd.'s Solid Pharmaceutical Polyethylene Bottled Silica Gel Desiccant was non-compliant regarding its "Moisture Absorption Rate."The SMFDA has mandated that involved companies immediately implement risk control measures, including suspending sales, halting use, and initiating recalls for affected products. Regulatory departments are tasked with investigating and penalizing illegal activities. Furthermore, companies are required to thoroughly investigate the root causes of these issues, develop, and execute corrective actions to eliminate potential risks, with ongoing daily supervision from local market supervision bureaus.